安科生物(300009.SZ):2023年度淨利潤預增10.90%-30.81%
格隆匯1月31日丨安科生物(300009.SZ)公佈2023年度業績預吿,報吿期歸屬於上市公司股東的淨利潤盈利78,000萬元—92,000萬元,比上年同期增長10.90%—30.81%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤盈利74,200萬元—88,200萬元,比上年同期增長15.57%—37.38%。
報吿期內,公司圍繞年度經營計劃夯實經營管理工作,主營業務收入穩步增長,延續了公司整體業績穩健增長的態勢,助力公司高質量發展。報吿期內,公司股權激勵費用攤銷約為7,364萬元;公司加大研發投入、生產線建設,持續推進主營產品升級及新產品的研究開發。股權激勵費用攤銷,以及研發費用、生產成本等成本費用的增加影響了淨利潤增長。報吿期內,非經常性損益對淨利潤的影響金額預計約為3,800萬元,上年度同期非經常性損益對淨利潤的影響金額為6,129.68萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.